Form 4: CervoMed Director Frank Zavrl Acquires Stock Options Following Board Election

Frank Zavrl, a director of CervoMed Inc., was granted options to purchase 5,750 shares of common stock on June 14, 2024, following his election to the board.

Summary

• Frank Zavrl, a director at CervoMed Inc. (CRVO), filed a Form 4 on June 14, 2024.
• The filing reports that Zavrl was granted an option to purchase 5,750 shares of CervoMed's common stock.
• This grant was in connection with Zavrl's election to the Issuer's board of directors at its 2024 Annual Meeting of Stockholders.
• The option has an exercise price of $19.01.
• The options vest monthly over a one-year period, starting June 30, 2024, contingent upon continued service as a director.
• The option expires on June 14, 2034.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The granting of stock options is a standard practice and aligns the director's interests with shareholders. There are no immediate negative implications.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders.
• The vesting schedule incentivizes continued service on the board.

Future Outlook

The director's compensation is tied to the company's performance through stock options, incentivizing value creation.

Industry Context

Granting stock options to board members is a common practice to align their interests with shareholders and incentivize long-term value creation. This is a standard component of director compensation packages in publicly traded companies.

Comparison to Industry Standards

• Director compensation packages, including stock options, are common across the biotechnology industry to attract and retain qualified board members.
• Companies like Amgen, Biogen, and Gilead Sciences also utilize equity-based compensation for their directors.
• The vesting schedule and exercise price are typical components of these packages, designed to incentivize long-term value creation.

Stakeholder Impact

• Shareholders may view this positively as it aligns the director's interests with the company's long-term success.
• Employees may see this as a sign of confidence in the company's future.

Key Dates